Home » Stocks » ONTX

Onconova Therapeutics, Inc. (ONTX)

Stock Price: $0.995 USD -0.025 (-2.49%)
Updated Mar 8, 2021 4:00 PM EST - Market closed
After-hours: $0.955 -0.040 (-3.98%) Mar 8, 5:11 PM
Market Cap 241.34M
Revenue (ttm) 204,000
Net Income (ttm) -24.48M
Shares Out 180.88M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 8
Last Price $0.995
Previous Close $1.020
Change ($) -0.025
Change (%) -2.49%
Day's Open 0.993
Day's Range 0.934 - 1.060
Day's Volume 16,818,751
52-Week Range 0.190 - 1.930

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 4 days ago

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Thursday, March 11, 2021

GlobeNewsWire - 1 week ago

NEWTOWN, PA., March 01, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for p...

Benzinga - 1 week ago

Onconova Therapeutics (NASDAQ: ONTX) shares are trading higher today after the company announced it regained compliance with the Nasdaq listing requirement. Onconova Therapeutics, Inc. is a bi...

The Motley Fool - 2 weeks ago

Investors are eager to hear more about the biotech's experimental cancer treatments.

InvestorPlace - 2 weeks ago

Onconova Therapeutics (ONTX) stock is on the rise Wednesday following the closing of its most recent public offering of 28.75 million shares. The post ONTX Stock: Why Biopharma Onconova Therap...

GlobeNewsWire - 2 weeks ago

NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to tre...

GlobeNewsWire - 2 weeks ago

NEWTOWN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for pa...

GlobeNewsWire - 3 weeks ago

NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to tre...

GlobeNewsWire - 3 weeks ago

NEWTOWN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to tre...

GlobeNewsWire - 2 months ago

NEWTOWN, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to tre...

InvestorPlace - 3 months ago

Onconova Therapeutics (ONTX) stock is on the move Tuesday with heavy trading despite a lack of recent news from the company. The post Onconova Therapeutics: 7 Things for ONTX Stock Investors t...

GlobeNewsWire - 3 months ago

NEWTOWN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, to...

Seeking Alpha - 3 months ago

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 3 months ago

Conference call begins at 4:30 p.m. ET today

GlobeNewsWire - 4 months ago

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 12 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, November 12

GlobeNewsWire - 4 months ago

NEWTOWN, Pa., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a biopharmaceutical company focused on discovering and developing novel products to treat cancer, to...

GlobeNewsWire - 5 months ago

Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021

GlobeNewsWire - 6 months ago

Onconova remains focused on development of its proprietary pipeline of targeted agents as it enters a new phase as a biopharmaceutical company Onconova remains focused on development of its pr...

Zacks Investment Research - 6 months ago

Onconova's (ONTX) shares fall more than 60% after its phase III study on intravenous rigosertib in patients with higher-risk myelodysplastic syndromes did not meet the primary endpoint.

24/7 Wall Street - 6 months ago

Onconova Therapeutics Inc. (NASDAQ: ONTX) was absolutely crushed to start out the week after the company reported results from its late-stage cancer study.

GlobeNewsWire - 6 months ago

IV rigosertib did not meet primary endpoint of significantly improved survival versus best supportive care in higher-risk myelodysplastic syndromes (HR-MDS)

Seeking Alpha - 6 months ago

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2020 Results - Earnings Call Transcript

Benzinga - 6 months ago

Shares of Onconova Therapeutics (NASDAQ:ONTX) decreased 1.89% in after-market trading after the company reported Q2 results.

GlobeNewsWire - 6 months ago

Conference call and webcast scheduled today, August 12, at 4:30 p.m. ET

GlobeNewsWire - 7 months ago

Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12 Company to host conference call and webcast at 4:30 p.m. Eastern Time on Wednesday, August 12

GlobeNewsWire - 7 months ago

NEWTOWN, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to ...

Zacks Investment Research - 7 months ago

Investors will focus on pipeline updates when Onconova (ONTX) reports Q2 results.

GlobeNewsWire - 7 months ago

Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020 Topline INSPIRE Results are Expected by the End of the Third Quarter of 2020

GlobeNewsWire - 7 months ago

NEWTOWN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to ...

GlobeNewsWire - 8 months ago

RAS-focused mechanism of action and manageable side effect profile indicate potential promise for oral rigosertib as part of future combination therapies

Zacks Investment Research - 8 months ago

Onconova (ONTX) starts investigator-initiated phase I/IIa study of oral rigosertib plus Bristol-Myers Squibb's Opdivo in advanced metastatic KRAS-mutated lung adenocarcinoma.

GlobeNewsWire - 8 months ago

NEWTOWN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to ...

GlobeNewsWire - 8 months ago

NEWTOWN, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to ...

GlobeNewsWire - 8 months ago

RAS Pathway Mutations Were Observed More Commonly in Patients That Progressed on HMA Therapy vs Patients That Failed HMA Therapy Completely RAS Pathway Mutations Were Observed More Commonly in...

Seeking Alpha - 9 months ago

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 9 months ago

Conference Call and Webcast Scheduled Today, May 14 at 4:30 p.m. ET Conference Call and Webcast Scheduled Today, May 14 at 4:30 p.m. ET

GlobeNewsWire - 9 months ago

NEWTOWN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to t...

Seeking Alpha - 11 months ago

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q4 2019 Results - Earnings Call Transcript

GlobeNewsWire - 11 months ago

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Tuesday, March 24, 2020 Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time on Tuesday, March 24, 2020

Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor in Onconova Therapeutics.

Zacks Investment Research - 1 year ago

Onconova (ONTX) will focus on the updates on lead candidate, Rigosertib, when it reports fourth-quarter 2019 results.

Seeking Alpha - 1 year ago

Onconova: The Ingredients For Success Are Finally Here

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor of Onconova Therapeutics, Inc. (ONTX).

Zacks Investment Research - 1 year ago

The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.

Other stocks mentioned: ABEO, APLT, EBF, PTI
GlobeNewsWire - 1 year ago

NEWTOWN, Pa., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cance...

GlobeNewsWire - 1 year ago

NEWTOWN, Pa., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing...

GlobeNewsWire - 1 year ago

NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing...

GlobeNewsWire - 1 year ago

NEWTOWN, Pa., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing...

GlobeNewsWire - 1 year ago

NEWTOWN, Pa., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing...

GlobeNewsWire - 1 year ago

NEWTOWN, Pa., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer...

About ONTX

Onconova Therapeutics, a biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and a dose-escalation and expansion Phase 1 trial is planned in the U.S. The company's product candidate oral rigosertib is currently in a dose-esc... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2013
CEO
Steven Fruchtman
Employees
17
Stock Exchange
NASDAQ
Ticker Symbol
ONTX
Full Company Profile

Financial Performance

In 2019, ONTX's revenue was $2.18 million, an increase of 77.77% compared to the previous year's $1.23 million. Losses were -$21.50 million, 4.52% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ONTX stock is "Buy." The 12-month stock price forecast is 2.10, which is an increase of 111.14% from the latest price.

Price Target
$2.10
(111.14% upside)
Analyst Consensus: Buy